Effects of light on metalloporphyrin‐treated newborn mice

Zinc protoporphyrin (ZnPP) is a promising metalloporphyrin with sufficient potency, but has poor solubility and is not absorbed well orally. Intragastric administration of ZnPP microparticles (30 μmol/kg) to 3‐day‐old mice resulted in a twofold increase in potency and no signs of phototoxicity.

[1]  D. Stevenson,et al.  Effect of light exposure on metalloporphyrin-treated newborn mice , 2012, Pediatric Research.

[2]  D. Stevenson,et al.  Metalloporphyrins – An Update , 2012, Front. Pharmacol..

[3]  D. Stevenson,et al.  Effects of Zinc Deuteroporphyrin Bis Glycol on Newborn Mice After Heme Loading , 2011, Pediatric Research.

[4]  D. Stevenson,et al.  In vitro inhibition of heme oxygenase isoenzymes by metalloporphyrins , 2011, Journal of Perinatology.

[5]  K. Cal,et al.  Spray drying technique: II. Current applications in pharmaceutical technology. , 2010, Journal of pharmaceutical sciences.

[6]  K. Cal,et al.  Spray drying technique. I: Hardware and process parameters. , 2010, Journal of pharmaceutical sciences.

[7]  M. Eslamian,et al.  Recent advances in nanoparticle preparation by spray and micro-emulsion methods. , 2009, Recent patents on nanotechnology.

[8]  B. Poindexter,et al.  Aggressive vs. conservative phototherapy for infants with extremely low birth weight. , 2008, The New England journal of medicine.

[9]  Reinhard Vehring,et al.  Pharmaceutical Particle Engineering via Spray Drying , 2007, Pharmaceutical Research.

[10]  D. Stevenson,et al.  Pharmacology Review: Tin Mesoporphyrin for the Prevention of Severe Neonatal Hyperbilirubinemia , 2007 .

[11]  Subcommittee on Hyperbilirubinemia.  Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. , 2004, Pediatrics.

[12]  Hui Zhao,et al.  Selection of potential therapeutics based on in vivo spatiotemporal transcription patterns of heme oxygenase-1 , 2002, Journal of Molecular Medicine.

[13]  D. Stevenson,et al.  Alternative Metalloporphyrins for the Treatment of Neonatal Jaundice , 2001, Journal of Perinatology.

[14]  L Yu,et al.  Amorphous pharmaceutical solids: preparation, characterization and stabilization. , 2001, Advanced drug delivery reviews.

[15]  K. Mäder,et al.  Solid lipid nanoparticles: production, characterization and applications. , 2001, Advanced drug delivery reviews.

[16]  S J Prestrelski,et al.  Biopharmaceutical powders: particle formation and formulation considerations. , 2000, Current pharmaceutical biotechnology.

[17]  D. Stevenson,et al.  Selective inhibition of heme oxygenase, without inhibition of nitric oxide synthase or soluble guanylyl cyclase, by metalloporphyrins at low concentrations. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[18]  C. Hammerman,et al.  Bilirubin conjugation, reflected by conjugated bilirubin fractions, in glucose-6-phosphate dehydrogenase-deficient neonates: a determining factor in the pathogenesis of hyperbilirubinemia. , 1998, Pediatrics.

[19]  D. Stevenson,et al.  Rhesus Isoimmunization: Increased Hemolysis during Early Infancy , 1997, Pediatric Research.

[20]  D. Stevenson,et al.  Duration of Action and Tissue Distribution of Zinc Protoporphyrin in Neonatal Rats , 1996, Pediatric Research.

[21]  D. Stevenson,et al.  Characterization of porphyrin heme oxygenase inhibitors. , 1996, Canadian journal of physiology and pharmacology.

[22]  H. Schulman,et al.  Inhibition of hippocampal heme oxygenase, nitric oxide synthase, and long-term potentiation by metalloporphyrins , 1994, Neuron.

[23]  D. Stevenson,et al.  Direct Relationship of Fetal Carboxyhemoglobin with Hemolysis in Alloimmunized Pregnancies , 1994, Pediatric Research.

[24]  C. Henschke,et al.  Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin. , 1994, Pediatrics.

[25]  D. Stevenson,et al.  Targeting Zinc Protoporphyrin Liposomes to the Spleen Using Reticuloendothelial Blockade with Blank Liposomes , 1993, Pediatric Research.

[26]  A. Kappas,et al.  Targeted Delivery of a Heme Oxygenase Inhibitor with a Lyophilized Liposomal Tin Mesoporphyrin Formulation , 1993, Pharmaceutical Research.

[27]  D. Stevenson,et al.  Selection of Metalloporphyrin Heme Oxygenase Inhibitors Based on Potency and Photoreactivity , 1993, Pediatric Research.

[28]  D. Stevenson,et al.  Jaundice in healthy, term neonates: do we need new action levels or new approaches? , 1992, Pediatrics.

[29]  D. Stevenson,et al.  In vitro and in vivo characteristics of a heme oxygenase inhibitor: ZnBG. , 1991, The American journal of the medical sciences.

[30]  D. Stevenson,et al.  Neonatal hyperbilirubinemia and physical and cognitive performance at 17 years of age. , 1991, Pediatrics.

[31]  N. L. Greenbaum,et al.  Tin(Sn+4)-diiododeuteroporphyrin; an in vitro and in vivo inhibitor of heme oxygenase with substantially reduced photoactive properties. , 1991, The Journal of pharmacology and experimental therapeutics.

[32]  D. Stevenson,et al.  Zinc protoporphyrin administration for suppression of increased bilirubin production by iatrogenic hemolysis in rhesus neonates. , 1990, The Journal of pediatrics.

[33]  A. Kappas,et al.  Targeting of heme oxygenase inhibitors to the spleen markedly increases their ability to diminish bilirubin production. , 1989, Pediatrics.

[34]  D. Stevenson,et al.  In Vitro Inhibition of Adult Rat Intestinal Heme Oxygenase by Metalloporphyrins , 1989, Pediatric Research.

[35]  D. Stevenson,et al.  The use of metalloporphyrins for the chemoprevention of neonatal jaundice. , 1989, American journal of diseases of children.

[36]  D. Stevenson,et al.  Effects of oral administration of tin and zinc protoporphyrin on neonatal and adult rat tissue heme oxygenase activity. , 1988, Journal of pediatric gastroenterology and nutrition.

[37]  M. Maines.  Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  S. Hintz,et al.  Recovery of Exogenous Heme as Carbon Monoxide and Biliary Heme in Adult Rats After Tin Protoporphyrin Treatment , 1987, Journal of pediatric gastroenterology and nutrition.

[39]  G. Drummond,et al.  Control of heme metabolism with synthetic metalloporphyrins. , 1986, The Journal of clinical investigation.

[40]  M. Maines,et al.  Prevention of neonatal hyperbilirubinaemia in non-human primates by Zn-protoporphyrin. , 1985, The Biochemical journal.

[41]  D. W. Smith,et al.  Bilirubin Production After Supplemental Oral Vitamin E Therapy in Preterm Infants , 1985, Journal of pediatric gastroenterology and nutrition.

[42]  K. Anderson,et al.  Control of Heme Oxygenase and Plasma Levels of Bilirubin by a Synthetic Heme Analogue, Tin‐Protoporphyrin , 1984, Hepatology.

[43]  G. Drummond,et al.  Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[44]  V. Hanson,et al.  CNS abnormalities after neonatal hemolytic disease or hyperbilirubinemia. A prospective study of 405 patients. , 1969, American journal of diseases of children.

[45]  H. Marver,et al.  The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[46]  T. Valaes,et al.  Neonatal Jaundice in Glucose - 6 - Phosphate - Dehydrogenase - Deficient Infants , 1962, British medical journal.

[47]  D. Stevenson,et al.  Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. , 1995, The Journal of pediatrics.

[48]  D. Stevenson,et al.  Role of Lipid Peroxidation in Metalloporphyrin-Mediated Phototoxic Reactions in Neonatal Rats , 1993, Pediatric Research.

[49]  H. Vallier,et al.  Oral administration of zinc deuteroporphyrin IX 2,4 bis glycol inhibits heme oxygenase in neonatal rats. , 1991, Developmental pharmacology and therapeutics.

[50]  H. Vallier,et al.  Absorption of zinc deuteroporphyrin IX 2,4-bis-glycol by the neonatal rat small intestine in vivo. , 1991, Developmental pharmacology and therapeutics.

[51]  D. Stevenson,et al.  Heme catabolism in rhesus neonates inhibited by zinc protoporphyrin. , 1990, Developmental pharmacology and therapeutics.

[52]  H. Vreman,et al.  Increased carbon monoxide excretion in Bolivian squirrel monkeys with fasting hyperbilirubinemia. , 1990, Journal of medical primatology.

[53]  D K Stevenson,et al.  Heme oxygenase activity as measured by carbon monoxide production. , 1988, Analytical biochemistry.

[54]  M. Maines.  Zinc . protoporphyrin is a selective inhibitor of heme oxygenase activity in the neonatal rat. , 1981, Biochimica et biophysica acta.